AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca plc (LON: AZN) said on Thursday that its net profit in the second quarter came in stronger on a year over year basis. The company also highlighted that its candidate vaccine for the treatment of COVID-19 is now in late-stage trials.

AstraZeneca’s net profit jumps to £581.18 million in the second quarter

AstraZeneca earnings and revenue easily beat views. The U.K. drug giant is working on a coronavirus vaccine.

AstraZeneca Earnings Rise; AZN Stock Signals Move Back Into Buy Zone

AstraZeneca plc (NYSE: AZN) second-quarter earnings beat estimates as demand for its therapies centered on diabetes and cancer remained strong, with the drugmaker also working on a potential coronavirus vaccine.

AstraZeneca Reports Q2 Earnings Beat On The Back Of A Diversified Drug Portfolio

The British firm is just one company working on a potential coronavirus vaccine.

'We don't know': AstraZeneca CEO says 'unpredictable' coronavirus may require annual vaccinations

Drugmaker AstraZeneca topped second-quarter sales and profit expectations on Thursday and stood by its 2020 forecasts, helped by strong sales in lockdowns of a diverse line-up, which now includes a potential coronavirus vaccine.

AstraZeneca tops forecasts on strong drug sales, outlook unchanged

AstraZeneca (NYSE: AZN) announces its next round of earnings this Thursday, July 30.

Earnings Preview: AstraZeneca

BioNTech SE

Catalent

Emergent BioSolutions

Johnson & Johnson

Lonza Group AG

Moderna

Novavax

Pfizer

The Race To Erase COVID-19

First Trust Nasdaq Pharmaceuticals ETF 

Amplify Treatments Testing & Advancements ETF

Renaissance IPO ETF

VanEck Vectors Pharmaceutical ETF

Invesco DWA Healthcare Momentum ETF

Vaxart

There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.

COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries

Here's why AstraZeneca agreed to pay Daiichi Sankyo another enormous sum to develop and commercialize an experimental cancer drug.

4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront

Delta Air Lines

Southwest Airlines

Park Hotels & Resorts

Penn Virginia

Ryman Hospitality Properties

Spirit Airlines

Hotel, Airline And Oil Stocks To Consider When The Pandemic Fades And Vaccine Arrives

There could be an even larger contract coming if the vaccine to prevent COVID-19 is successful.

Emergent BioSolutions Triples Its Coronavirus-Vaccine Manufacturing Contract With AstraZeneca

Gilead Sciences

GlaxoSmithKline

Eli Lilly

Merck

Sanofi

Several major U.S. drugmakers will report second-quarter results this week, with investors eager for fresh details from Pfizer Inc , Merck & Co and others on their efforts to develop vaccines and therapies against the novel coronavirus.

U.S. drugmaker earnings heat up this week with spotlight on vaccine news

AstraZeneca on Monday unveiled a cancer treatment partnership with a Japanese company that could be worth as much as $6 billion and aims for best-in-class treatment of lung and other cancer.
The post AstraZeneca Inks Multibillion-Dollar Cancer Treatment Collaboration appeared first on Investor's Business Daily.

AstraZeneca Inks Multibillion-Dollar Cancer Treatment Collaboration

Persimmon PLC

Turbulence looks set to continue going forward in the market as uncertainty remains prevalent.

3 U.K. Yielders I'm Buying Through Turbulence

AstraZeneca will pay up to $6 billion to Japan's Daiichi Sankyo under the drugmakers' second multi-billion dollar oncology collaboration to develop and market a new type of targeted cancer treatment.

AstraZeneca bets up to $6 billion on new Daiichi cancer drug

Shares of Emergent BioSolutions Inc. EBS, +1.01% were up 0.1% in premarket trading on Monday after the company said it will provide contract development manufacturing services for AstraZeneca's AZN, +1.14% AZN, -0.48% COVID-19 vaccine candidate for $174 million.

Emergent to provide manufacturing services on AstraZeneca's COVID-19 vaccine

AstraZeneca plc (NYSE: AZN) announced Monday that it is collaborating with Japanese pharmaceutical giant Daiichi Sankyo Company, Limited (OTC: DSNKY) on a new cancer drug.

AstraZeneca To Pay $6B To Japan's Daiichi As Part of Collaboration On New Cancer Drugs

TOKYO, MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062

Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062

Inovio Pharmaceuticals

Let's take a look at what's happened so far and what's on the horizon.

Here's Your Guide to the Coronavirus Vaccine Leaders

One coronavirus vaccine candidate in phase 3 testing might have the best shot at achieving commercial success.

5 Late-Stage COVID-19 Vaccines: Which Is Likely to Be the Biggest Winner?

Bristol-Myers

Each of these big drugmakers offers strong growth prospects and solid dividends.

3 Top Pharma Stocks to Buy Right Now

Despite positive news this week regarding its COVID-19 vaccine, AstraZeneca shares dropped due to concerns about side effects and market competitiveness.

Why AstraZeneca Shares Slumped This Week Despite Positive Vaccine News

The good doctor is somewhat less optimistic than the leading coronavirus vaccine developers about timing.

Fauci: Coronavirus Vaccine Likely Not "Widely Available" Until Several Months Into 2021

It was the press announcement heard around the world: a potential Covid-19 vaccine from the University of Oxford and pharmaceutical company AstraZeneca had not only been “tolerated” by patients, but “generated robust immune responses against the Sars-CoV-2 virus in all evaluated participants”. The project will now proceed to all-important phase 3 trials in Brazil and South Africa to test if it actually stops infection.

Covid-19 is Big Pharma’s chance to impress. But who’ll do best?

You have to look at more than just their COVID-19 programs.

Better Coronavirus Stock: AstraZeneca vs. Moderna

News for AstraZeneca Stock (AZN)